Will Novo Nordisk Get Lift From Gut-Brain Axis?
Victoza Data In Alzheimer's May Signal Opportunity For GLP-1 Class.
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.
You may also be interested in...
Novo Nordisk said late stage clinical trials near completion would not be hit by the pandemic but that delays to other stage studies were likely, and new ones were now “on hold.”
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.